SSG
RDY icon

Summit Securities Group’s Dr. Reddy's Laboratories RDY Stock Holding History

Summit Securities Group’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2,500
Closed -$19K – 528
2013
Q2 		$19K Buy
+2,500
New +$18.3K 0.01% 255

Other funds holding RDY

CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $355M AUM
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Summit Securities Group's RDY Position: Q3 2013 in Review

Summit Securities Group sold out of Dr. Reddy's Laboratories (RDY) in Q3 2013, closing a stake of 2,500 shares — an estimated $19K sold.

Summit Securities Group first reported a position in RDY in Q2 2013 and held it in 1 quarter. The position peaked at $19K in Q2 2013. 141 funds tracked by Wall St. Rank hold RDY as of Q3 2013.

  • Summit Securities Group reported no remaining Dr. Reddy's Laboratories position as of Q3 2013 after selling out during the quarter.
  • Summit Securities Group sold 2,500 Dr. Reddy's Laboratories shares in Q3 2013, an estimated $19K.
  • Summit Securities Group first reported a position in Dr. Reddy's Laboratories in Q2 2013 and held it in 1 quarter.
  • Summit Securities Group's Dr. Reddy's Laboratories position peaked at $19K in Q2 2013.
  • 141 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2013.

Based on Summit Securities Group's 13F filing for Q3 2013, filed 1 Nov 2013.